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Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening immune dysregulation syndrome characterized by uncontrolled
immune cell activation. Timely diagnosis is important, since early treatment can improve survival rates. However, completing all
assessments needed to reach ≥5 positive criteria out of the 8 HLH-2004 criteria can be time consuming and may delay timely initiation
of treatment. Hence, we applied a data-driven approach to identify a minimal parameter set for early decision-making towards the
initiation of HLH-specific treatment. We retrospectively evaluated 165 patients from five Dutch tertiary hospitals with suspected HLH.
Sixteen pHLH (median age 0.5 years) and 70 sHLH patients (median age 8.7 years) were identified using the HLH-2004 criteria.
Clustering analysis and multi-receiver operator characteristics were used to identify parameters distinctive of HLH. The presence of
either increased ferritin, cytopenia in ≥2 lineages, or splenomegaly distinguished HLH from non-HLH cases with a negative predictive
value of 100%. Aminimal parameter set consisting of 2major criteria (phagocytosis and splenomegaly) and 3minor criteria (cytopenia,
increased ferritin, and increased triglycerides/low fibrinogen) predicted HLHwith 95% (88–99) sensitivity and 94% (86–98) specificity.
This finding was replicated in an independent retrospective validation cohort of 109 US patients (n= 109). By dividing a subset of the
HLH-2004 criteria into major and minor criteria, this strategy uses the evaluation of less than 5 criteria to quickly identify patients with
HLH. When confirmed in a prospective setting, this approach could be of value for timely diagnosis and treatment of HLH.
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Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a life-
threatening immune dysregulation syndrome characterized
by uncontrolled immune cell activation. [1, 2] Activated lym-
phocytes and macrophages produce a cytokine storm that in-
duces hemophagocytosis and tissue phagocytosis by
overactivated macrophages. [1, 3, 4] HLH eventually results
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in multiple organ failure that culminates in mortality in up to
50% of affected children and adults. [1, 3, 5, 6]
The two subtypes of HLH include primary HLH (pHLH)
and secondary HLH (sHLH). pHLH is a group of diseases
caused by germ line mutations in genes involved in vital im-
munologic pathways. [7, 8] Several pHLH disorders are clus-
tered as familial HLH, in which defective T and NK lympho-
cyte function causes a failure in the termination of the immune
response as well as persistent antigenemia that stimulates the
immune system and induces the cytokine storm. [9–11]
Secondary HLH can be induced by infection (42%), cancer
(40%), or autoimmune disease (11%). [1, 4, 9–12] [4, 13]
The diagnosis of HLH forms a challenge since many of its
symptoms are nonspecific. [14, 15] HLH is currently diagnosed
according to the presence of at least 5/8 of the HLH-2004 criteria:
fever, splenomegaly, increased ferritin, high soluble cluster of
differentiation 25 (sCD25), cytopenia in at least two cell lineages,
tissue phagocytosis, lowNK lymphocyte–mediated lysis of target
cells, and either high triglycerides or low fibrinogen. [16] Since
the triggers for HLH vary, it is assumed to be a heterogeneous
disease and there is debate whether this heterogeneity has impli-
cations for the diagnostic process. [17, 18] For example, there is
evidence that patients with malignancy-induced HLH present
with different HLH-related parameters when compared to HLH
patients with other underlying diseases. [18–20] Lastly, the diag-
nostic properties of the NK lysis assays and the sCD25 assays
remain uncertain for the diagnosis of HLH. These laboratory tests
can be time consuming and are restricted to specialized centers,
which may delay definitive diagnosis and treatment. [18–21]
Early recognition of HLH is imperative as timely adminis-
tration of immunosuppressant drugs prevents aggravation of
immune dysregulation. This was suggested in a previous ret-
rospective analysis showing a correlation between early
etoposide administration and survival. [12]
Since the current HLH criteria involve a subset of laborious
tests, and early treatment is essential, the question arises
whether a subset of the currently used HLH criteria can be
used as a reliable first screening to assess the risk for HLH.
Hence, the objective of this study was to identify a minimal
parameter set required to predict HLH that could serve as a tool
for early therapeutic decision-making. To this end, a data-driven
statistical analysis approach was applied in a Dutch retrospective
discovery cohort of HLH-suspected children and adults and the
determined minimal parameter set was subsequently confirmed
in an American retrospective cohort of HLH suspected adults.
Methods
Clinical Record Review and Cohort Acquisition
After approval of the medical ethical committee (METC nr.
17/111), we retrospectively evaluated the clinical records of
264 patients from 5 academic medical centers in the
Netherlands for whom NK/lymphocyte function tests or
sCD25 assays had been performed between 2006 and 2016.
After reviewing the patient records, the records of 99 patients
were excluded since they were either not evaluated according
to the HLH-2004 criteria or too many HLH-2004 criteria were
missing to exclude HLH. The records of 165 patients were
selected for further review. Fulfilment of ≥5 of the 8 HLH-
2004 criteria and/or confirmed germline mutations associated
with pHLHwere used to establish HLH diagnosis. The results
of all 8 HLH-2004 criteria assessments were collected from
the electronic records together with patient characteristics
such as age, gender, and final diagnosis.
NK/Lymphocyte Function and sCD25 Analyses
NK lymphocyte functional testing was performed in a central
diagnostic reference center (Laboratory of Translational
Immunology, UMC Utrecht) using CD107a degranulation
andNK target cell lysis assays. For both assays, PBMC’s were
isolated and cell subsets were counted. For the CD107a assay,
PBMC’s were incubated with K562 tumor cells and CD8+
CD107a+ cells were counted using flow cytometry. For the
NK lysis assay, two effector (NK lymphocytes) vs target
(K562 tumor cells) ratios (1:1 and 2:1) were used and NK
lysis was analyzed using Celltrace violet© and flow cytome-
try. Moreover, NK lymphocyte function panels from healthy
siblings that were not investigated for HLH were included for
the analysis of the sensitivity and specificity of the NK lym-
phocyte function assays.
sCD25 was measured in individual hospitals using the
Diaclone© (upper limit of normal: 2500 pg/mL) or
Immulite© (upper limit of normal: 7500 pg/mL) enzyme-
linked immunosorbent assays (ELISA) according to the man-
ufacturer’s instructions. We normalized the data by calculat-
ing a fold change relative to the upper limit of normal of the
used test kit.
Validation Cohort
The validation cohort consisted of 109 sHLH patients and 38
non-HLH patients from the Hematology Division of Johns
Hopkins Hospital in Baltimore, MD. These patients were ret-
rospectively acquired from billing and lab results and classi-
fied according to the HLH-2004 criteria between January 1,
2009, and August 1, 2018, as previously published. [22]
Diagnostic criteria were recorded and peak values for ferritin
and triglycerides and fibrinogen nadir values were also noted.
HLH was defined by the HLH-2004 criteria. Data collection
was approved by the Johns Hopkins Institutional Review
Board. Data on the patients was de-identified by the treating
physician before data analysis.
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Statistics
Statistics were performed in R studio 1.1.456, which was used
to compare proportions of positive parameters between the
different groups of HLH patients and produce a heatmap of
these parameters. Then, the “mixomics” package was used for
a partial least squares discriminant analysis (PLS-DA) to find
characterizing parameters in a supervised method.
Furthermore, the “psych” and “GPArotations” packages were
used to perform a principal component analysis (PCA), after
single stochastic regression imputation of missing data with
the “amelia” package, to find characterizing parameters in an
unsupervised method. The first three principal components
were used in further analyses since they explained most of
the variance within the dataset.
Multi-receiver operator characteristics (multiROC) curves
were calculated by using generalized linear modelling with
pROC and R’s inbuilt statistics packages to compare the di-
agnostic models. Lastly, cutoff values for NK/lymphocyte
function were defined by calculating the Δ and the fold change
of the 1:1 vs 2:1 dilution. R’s “Optimal.Cutpoints” and “epiR”
packages were used to calculate sensitivity and specificity of
the proposed new algorithms.
Results
Prevalence of the 8 HLH-2004 Criteria in HLH
Subgroups
One hundred sixty-five HLH suspected patients were included
in the primary cohort. After evaluating the HLH-2004 criteria,
we had 79 non-HLH and 86 HLH patients (16 pHLH and 70
sHLH). The median age of the pHLH group was 0.5 (0–50.7)
years, 8.7 (0–83) years in the sHLH group and 9.7 (0–84)
years in the non-HLH group. The type of pHLH and the af-
fected gene and genetic variants of the pHLH patients includ-
ed in this study are reported in supplementary table 1 and
included pathologic mutations in PRF1, UNC13D, STX11,
and STXBP2. The most common primary diagnosis in the
non-HLH group was either autoimmune disease (20.8%) or
immunodeficiency (20.8%), whereas infection (27%) and ma-
lignancy (24.3%) were the most common causes of sHLH
(Table 1). In 62% of the HLH cases (ranging from 58.8 to
100% among subgroups), hemophagocytosis was observed,
either in bone marrow aspirates and/or other affected tissue.
Patients with sHLH induced by autoimmune disease fulfilled
the cytopenia criterion less often and patients with sHLH in-
duced by infections more often had normal NK lysis assays,
suggesting that there was significant variation in positive
criteria between HLH subgroups. Moreover, significant vari-
ation also existed within the HLH subgroups, denoted by the
large standard deviations that were found. This was
underlined by the fact that the MHscore, a diagnostic tool that
differentiates pHLH from MAS, could not differentiate be-
tween pHLH and sHLH in this cohort. [23] The score showed
an AUC of 0.709, pHLH patients had a median score of 78.5
(60–99.25), and sHLH patients had a median score of 60 (34–
72). To identify common denominators of HLH between these
groups, we first tried a steered approach, followed by several
clustering methods.
The steered approach consisted of an evaluation of param-
eters that are readily available in the clinical setting: elevated
ferritin, cytopenias in ≥2 cell lines, and splenomegaly. We
hypothesized that these criteria may guide decision-making
towards additional HLH diagnostics. First, we calculated the
diagnostic properties of ferritin as sole marker for HLH. We
set the sensitivity to 90% and found that a ferritin value
787 μg/L enabled us to identify patients with HLH with
48% specificity and an AUC of 0.693. To improve this, we
then added the other criteria and observed that by adding
splenomegaly or severe cytopenia in >2 lineages (according
to the HLH-2004 criteria) to the model, the cutoff for ferritin
could be increased to 1000 μg/L. The presence of either
splenomegaly, severe cytopenia in >2 lineages (according to
the HLH-2004 criteria), or increased ferritin (>1000 μg/L)
yielded 100% sensitivity and 65% specificity with a negative
predictive value of 100% for HLH in the discovery cohort
(Supplementary, table 2).
Hierarchical Clustering
Different clustering analysis methods were used to determine
the parameters that could distinguish between HLH and non-
HLH patients and the different subtypes of HLH. First, hier-
archical clustering was applied to the 8 HLH-2004 criteria,
CNS symptoms, NK lymphocyte numbers, and bilirubin
levels. We found that even though no specific clusters were
formed, hierarchical clustering was moderately capable at sep-
arating the non-HLH patients from the HLH patients
(Fig. 1A). However, hierarchical clustering did not separate
the pHLH from sHLH patients (Fig. 1B), nor other subgroups
within the HLH spectrum. This suggests that there is no spe-
cific set of parameters that can distinguish the separate forms
of HLH within the HLH-2004 criteria.
Supervised Clustering with Dimension Reduction
Secondly, PLS-DA was used to maximize the chance of find-
ing discriminating clusters of criteria that could define the
sHLH subgroups and distinguish between sHLH and pHLH,
but none could be found (Supplementary, fig. 1). The criteria
that could identify HLH patients in general overlapped exces-
sively for the pHLH and sHLH patients and also for other
HLH subgroups. Hence, all subgroups were pooled for further
analysis.
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The results of the pooled PLS-DA are shown in Fig. 2A
and 2B. The combination of the presence of splenomegaly,
together with cytopenias, proven tissue hemophagocytosis,
fever, increased sCD25, and elevated triglycerides could dis-
tinguish HLH patients from non-HLH patients effectively
with an area under the curve (AUC) of 0.93. Moreover,
splenomegaly, biopsy-proven hemophagocytosis, and cytope-
nias are the most distinguishing parameters in this analysis.
Unsupervised Clustering with Dimension Reduction
Finally, a PCA analysis with oblique rotation was performed to
see if an unsupervised approachwould yield similar results as the
supervised approach. The Kaiser-Meyer-Olkin (KMO) measure
showed that there were too few samples to explain all variables,
which led to the exclusion of NK lysis 2:1, NK fold change and
age, since these had the poorest common variance. This resulted
in an overall KMO = 0.64 with no single value below 0.5.
Bartlett’s test of sphericity resulted in chi-squared (45) = 239,
p < 0.0001. The scree plot showed an “elbow” at four factors,
indicating that four factors were sufficient to explain most vari-
ance within the dataset. This was confirmed by the dimension
reduction data which showed that four factors had a cumulative
variance of 67%, of which the first three explained 81%
(Supplementary figure 2 & Supplementary table 3).
Cluster analysis showed that either PC1 or PC2 combined
with PC3 could distinguish between the non-HLH and HLH
patients (Fig. 2C). The variance in PC1 was mostly caused by
fever (0.74), triglycerides (0.65) and splenomegaly (0.55), and
biopsy-proven phagocytosis (0.55). For PC2, this was ferritin
(0.84), NK lysis (0.96), and sCD25 (0.35) and for PC3, leu-
kocytes (0.98), neutrophils (0.95), and platelets (0.55).
Simulating Minimal Parameter Sets with multiROC
Since tissue hemophagocytosis, splenomegaly and cytopenias
were defining parameters for HLH in both the PLS-DA and the
PCA; these criteria were used as initial parameter set. We then
simulated the minimal parameter set needed for HLH diagnosis,
by iteratively adding the criterion that caused the largest increase
in AUC (Supplementary, figure 3). This ultimately led to the
discovery of a combination of biopsy-proven hemophagocytosis,
splenomegaly, cytopenias in ≥2 lineages, ferritin ≥1000, and
⇑triglycerides/⇓fibrinogen with an AUC of 0.95. Further addi-
tion of the other criteria (fever, sCD25, and aberrant NK/
lymphocyte function assay) did not greatly improve the algo-
rithm (Fig. 2D, AUC 0.96–097), suggesting that these parame-
ters are not essential for the diagnosis of HLH.
Furthermore, since splenomegaly and biopsy-proven
hemophagocytosis clustered together in the PCA and were
also among the top discriminative parameters in the PLS-
DA, these criteria were analyzed asmajor criteria. The remain-
ing three criteria were analyzed as minor criteria and com-
pared to the golden standard, the HLH-2004 criteria, as
Table 1 Summary statistics on included patients. Non-HLH patients
were defined as patients who did not meet the HLH-2004 criteria. The
type of underlying disease was defined as the primary diagnosis that the
patient was suffering from (e.g., a patient suffering from SLE and
infection was scored as autoimmune; AI) The largest variation in symp-
tom positivity was seen in the presence of cytopenias and an aberrant NK
lysis assay. Moreover, splenomegaly, cytopenia, and elevated ferritin











Median age (range) 9 (0–84) 1 (0–51) 16 (1–40) 7 (0–47) 4 (0–64) 15 (1–83) 2 (0–58)
Gender (male) 64.5% 50% 63.6% 50% 100% 61.1% 71.4%
Fever > 38.5 °C (NA) 62.0% (0) 93.8% (0) 100% (0) 95.0% (0) 71.4% (0) 94.4% (0) 76.9% (1)
Splenomegaly (NA) 20.3% (0) 81.3% (0) 72.7% (0) 80.0% (0) 85.7% (0) 77.8% (0) 78.6% (0)
Proven HLH on biopsy (NA) 5.3% (41) 64.3% (2) 66.7% (2) 58.8% (0) 100% (0) 60.0% (3) 71.4% (0)
Cytopenias ≥ 2 (NA) 20.3% (0) 93.8% (0) 45.5% (0) 68.4% (1) 100% (0) 83.3% (0) 64.3% (0)
Ferritin ≥ 500 (NA) 67.7% (14) 100% (0) 90.9%(0) 100% (0) 50% (1) 100% (0) 100% (0)
Ferritin ≥ 1000 (NA) 43.1% (14) 81.3% (0) 81.8%(0) 80% (0) 50% (1) 83.3% (0) 85.7% (0)
- Mean ferritin levels (SD) 5020 (13662) 3379 (2597) 12,106 (10476) 28,689 (101621) 5576 (9017) 7510 (7825) 11,139 (21214)
⇑ Triglycerides/⇓ fibrinogen (NA) 31.8% (35) 86.7% (2) 63.6% (0) 68.4% (1) 66.7% (1) 64.7% (1) 54.5% (3)
- Mean triglyceride levels (SD) 2.47 (1.90) 4.65 (2.11) 4.05(2.23) 4.14(1.62) 2.93(3.03) 4.28(2.53) 3.70 (1.90)
- Mean fibrinogen levels (SD) 3.97 (2.54) 2.81 (3.46) 2.51(1.58) 2.63(1.61) 1.90(1.45) 3.39(1.60) 5.25 (5.98)
⇑ sCD25 (NA) 50.0% (21) 100% (3) 66.7% (2) 87.5% (4) 83.3% (1) 100% (3) 83.3% (2)
- Mean X upper reference value (SD) 4.9 (7) 24.0 (22) 6.2 (5) 13.7 (11) 23.0 (34) 15.0 (13) 18.5 (22)
Aberrant NK lysis assay (NA) 19.4% (48) 75% (12) 37.5% (3) 0% (9) 40% (2) 60% (13) 71.4% (6)
Median # of positive criteria (range) 2 (0–4) 7 (3–7) 5 (5–7) 6 (5–7) 5 (5–7) 6 (5–7) 5 (5–7)
CNS involvement (NA) 0% (49) 60% (1) 25% (3) 45.5% (9) 0% (2) 50% (6) 41.7% (1)
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presented in Table 2. HLH was most likely when a patient
either had 2 major positive criteria (48% sensitivity, 100%
specificity), 1 major and 2 minor positive criteria (79% sensi-
tivity, 95% specificity), or 3 minor positive criteria (49% sen-
sitivity, 97% specificity), with a combined sensitivity of 94%
and specificity of 95% (Table 2 and Fig. 3).
Analysis of the Minimal Parameter Set in the
Replication Cohort
The replication cohort consisted of 109 sHLH patients with a
median age of 58 (19–77) and 38 non-HLH patients with a
median age of 54 (19–81). The most common primary diagnosis
in the non-HLH group was autoimmune (47%), whereas malig-
nancy (39.4%) and infection (36.7%) were the most common
causes of sHLH in this cohort (Supplementary, table 4).
The minimal parameter set, which distinguished patients with
HLH from non-HLH patients when two major criteria were
positive (44% sensitivity, 100% specificity), one major and two
minor criteria were positive (87% sensitivity, 97% specificity), or
three minor criteria were positive (76% sensitivity, 97 specifici-
ty), could distinguish sHLH patients from non-HLH patients
with 98% sensitivity and 95% specificity which confirmed the
sensitivity and specificity of the minimal parameter set.
Furthermore, the presence of either splenomegaly, cytope-
nias in ≥2 cell lines, or ferritin ≥1000 μg/L yielded 100%
sensitivity and 16% specificity.
The Role of the NK/Lymphocyte Function and sCD25
Assays
Even though the NK/lymphocyte function and sCD25 assays
are not included in the minimal parameter set, they are part of
the HLH-2004 diagnostic criteria. We measured their perfor-
mance in this cohort as decisive fifth criterion in borderline
positive cases. There were 26 cases in which HLH was
Fig. 1 Hierarchical clustering dendogram that could moderately separate non-HLH patients (red) from HLH patients (blue). This clustering strategy
could not distinguish pHLH from sHLH patients (A) nor the subtypes of sHLH (B), based on these parameters
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Fig. 2 List of HLH defining symptoms that separate HLH patients from
non-HLH patients in a PLS-DA (A), with an AUC of 0.93 (B). PCA
showed that either PC1 (cytopenias, 32%) or PC2 (Ferritin/NK Lysis/
sCD25, 25%) with PC3 (Splenomegaly/Proven biopsy of HLH, 21%)
could separate HLH from non-HLH patients (C). MultiROC analysis
wielded a combination of splenomegaly, proven biopsy of HLH, cytope-
nias, elevated ferritin, and ⇑triglycerides/⇓fibrinogen as minimal param-
eter set with an AUC of 0.95 which did not significantly improve with the
addition of NK lysis or sCD25 (D)
Table 2 Analysis of the sensitivity and specificity of the minimal
parameter set that can predict HLH with splenomegaly and tissue
phagocytosis as major criteria and ferritin, cytopenia, and triglycerides/
fibrinogen as minor criteria. These were replicated in another retrospec-
tive cohort which produced similar results
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diagnosed based on the minimum of 5 positive criteria. Since
sensitivity of the NK/lymphocyte function assay was low
(Table 3), it could only be used as fifth positive criterion in
6/26 cases. Hence, we calculated a cutoff for the dilution se-
ries (n = 103, 62 non-HLH patients and 41 HLH patients) with
maximum sensitivity at a specificity of at least 90%, to im-
prove the diagnostic properties of the NK lysis assay, without
impairing its robustness. This wielded a cutoff fold change of
1.17 with an AUC of 0.602, which significantly improved the
diagnostic properties of the NK/lymphocyte function assay
(Table 3).
sCD25 has previously been suggested as a sensitive HLH
marker. [24] In our cohort, it was needed to get to 5 positive
criteria in 20/26 cases. To confirm previous findings, the per-
formance of sCD25 as sole indicator of HLHwas measured in
our cohort (n = 120, 59 non-HLH patients, 61 HLH patients).
Cutoffs were calculated with a minimum sensitivity of 90%
and with a minimum specificity of 90%, which were 2.63 and
11.8 respectively with an AUC of 0.806 (Table 2). These
results implicate that although NK lysis and sCD25 are not
needed for initial treatment initiation, they can be used to
acquire the five positive criteria needed for unambiguous di-
agnosis or to further support the diagnosis of HLH.
Discussion
Early diagnosis of HLH is indispensable for timely adminis-
tration of therapy to prevent aggravation of immune dysregu-
lation, clinical deterioration, and significant morbidity and
mortality. In this retrospective cohort analysis, we evaluated
the diagnostic value of the individual HLH-2004 criteria using
novel statistical methods including unsupervised hierarchical
cluster analysis and principal component analysis. We defined
a minimal parameter consisting of major and minor criteria for
identification of HLH patients, which could facilitate early
therapeutic decision-making for HLH.
In a rigid diagnostic approach, HLH is likely when 5/8 of
the HLH-2004 criteria have been met. This may delay timely
diagnosis, because several of these criteria require time-
consuming assays, which are not widely available. Delayed
diagnosis is especially threatening for severely ill patients.
Vice versa, it has been shown that early initiation of etoposide
improved survival in a retrospective study in 162 sHLH pa-
tients. Thus, any effort to facilitate an early diagnosis is im-
portant to reduce the high mortality of HLH. [12]
Failure to meet either the ferritin, cytopenia, or splenomeg-
aly criterion excluded HLH in our cohort. At the same time,
we found that this minimal parameter set consisting of 2 major
criteria (hemophagocytosis and splenomegaly) and 3 minor
criteria (cytopenia, increased ferritin, and increased
triglycerides/low fibrinogen), which can all be available
Fig. 3 Decision tree according to minimal parameter set for diagnosing
HLH and initiation of treatment. The separate sensitivity and specificity
of each argument is displayed as well as the combined sensitivity and
specificity of the minimal parameter set as a whole
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within 24 h, predicted HLH with 95% (88–99) sensitivity and
94% (86–98) specificity.
As with the HScore, which is used to facilitate early
identification of HLH in suspected cases, [25, 26] the num-
ber of criteria needed to predict HLH occurrence was re-
duced. Fever, the NK lysis assay, and sCD25 levels were
excluded from our model as initial diagnostics. An advan-
tage of our minimal parameter set is that we used the dis-
tinction of major and minor criteria and calculated the diag-
nostic properties of different sets of criteria, exactly
predicting the combined strength of these sets. [24] More
recently, other tools have been identified such as the MAS
classification criteria, the MS score, and the ESR/ferritin
ratio. [27–29] These have however only been confirmed in
patients with autoimmune disease-related HLH and hence,
their performance in the entire spectrum of HLH is un-
known. Since the minimal parameter set had a false positive
rate of 1:20, we still suggest to confirmHLH in all suspected
HLH patients with the full set of HLH-2004 criteria, com-
bined with genetic confirmation and evaluation of second-
ary triggers where indicated, to prevent longtime exposure
to immunosuppressants in non-HLH patients.
The results further showed that, in contrast to what is
known from previous cohorts, individual criteria such as fer-
ritin or sCD25 lacked either specificity or sensitivity. [15, 24,
30, 31] Patients with abnormal ferritin, sCD25, and NK lysis
values formed one cluster, suggesting that these parameters
are all indicators of severe systemic inflammation or critical
illness. This is in line with other studies showing that NK
lymphocyte–mediated target cell lysis, cytokine production,
and CD107a surface receptor expression were lower in ICU
patients compared to healthy controls. [32–34]
Data on the diagnostic value of ferritin as sole marker for
HLH remain inconclusive. [35, 36] We now show that it can
indicate patients for whom HLH diagnostics would be appro-
priate when assessed together with spleen size and the number
and severity of cytopenias. [15, 37] We thus advocate the
addition of ferritin measurement to the routine workup of pa-
tients with systemic inflammation. [35, 38–40]
Moreover, classical statistical methods and clustering
analysis could not distinguish pHLH from sHLH patients
in patients suspected of HLH based on the 8 HLH-2004
criteria, excluding pHLH patients in the analysis did not
alter the results, showing that in our cohort at least these
patients could be diagnosed identically. This was con-
firmed by the fact that the MHscore, which uses age of
onset combined with several HLH-2004 criteria, also
failed to distinguish pHLH from sHLH in this cohort.
Additionally, in contrast to a previous study, patients with
malignancy-induced HLH could not be distinguished from
patients with HLH induced by other underlying diseases.
[19, 41] This could be caused by the fact that we did not
study every parameter separately, but rather the relation
between the 8 criteria as a whole.
Limitations of our study warrant consideration. First, selec-
tion bias may have been introduced in this cohort, since the
HLH-2004 criteria were used stringently to identify HLH pa-
tients (following current clinical practice), which may have
led to underdiagnoses in this cohort, as borderline cases might
have been classified as non-HLH. This could be prevented by
using some of the newly proposed diagnostic tools (e.g.,
HScore, HLH in sJIA/SLE) and compare the outcomes with
the values from the HLH-2004 criteria. This would also have
enabled us to compare the performance of these scores and the
newly proposed tool. Moreover, the patient selection in the
discovery cohort may have been biased as only patients in
whom a NK lysis assay or sCD25 was measured were includ-
ed. Second, single stochastic regression imputation was used
to complete missing data in the PCA dataset. This approach
may have caused overidentification of interrelationships, as
noise inherent to such datasets is reduced. [42] However, this
effect was minimized by replicating our results in another
cohort. Even though this cohort contained more adults which
had other underlying etiologies, the minimal parameter set
could still identify HLH patients successfully. The specificity
of ferritin, cytopenias, and splenomegaly, as indicators of
HLH, was lower in the replication cohort, suggesting that
the non-HLH patients in this cohort were more similar to the
HLH patients. This might be caused by a different approach in
data inclusion or patient population. Third, although the dilu-
tion series have improved the diagnostic properties of the NK
lysis assay, there was a trend towards lower specificity in
comparison with the traditional NK/lymphocyte function as-
say. However, in the context of the 8 HLH-2004 criteria, the
introduction of the dilution series did not introduce false pos-
itive cases in our cohort.
Table 3 Analysis of the
performance of the current NK
lymphocyte function tests vs
addition of the dilution series as
sole predictor for HLH
(*p < 0.01) and sensitivity and
specificity cutoffs for sCD25 fold
change as HLH predictor
Test Sensitivity (95% CI) Specificity (95% CI)
Lysis <5% and CD107a <7% 0.27 (0.07–0.31) * 0.92 (0.83–0.97)
Foldchange <1.17 0.29 (0.16–0.45) 0.94 (0.84–0.98)
Combined Criteria 0.55 (0.39–0.70) * 0.87 (0.76–0.94)
sCD25>2.63x upper limit 0.93 (0.84–0.98) 0.40 (0.27–0.53)
sCD25>11.8x upper limit 0.42 (0.31–0.55) 0.91 (0.81–0.97)
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In conclusion, we determined that specific combinations of
the previously existent HLH-2004 criteria provide high spec-
ificity and sensitivity for a diagnosis of HLH. The minimal
HLH parameter set identified here may improve outcome of
HLH patients by facilitating rapid diagnosis of HLH in pa-
tients undergoing evaluation. When confirmed in a prospec-
tive setting, this approach could be of value for timely diag-
nosis and treatment of HLH.
Abbreviations HLH, Hemophagocytic lymphohistiocytosis; sHLH,
Secondary HLH; pHLH, Primary (familial) HLH; sCD25, Soluble cluster
of differentiation 25; PLS-DA, Partial least squares differential analysis;
AUC, Area under the curve; PCA, Principal component analysis;
multiROC, Multi-receiver operator characteristics
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